Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of June 2018, with a report date of June 14, 2018. The registrant is a foreign private issuer based in Givatayim, Israel, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material change disclosed is the resignation of Mark Groussman from the Board of Directors on June 11, 2018. The Company explicitly states that the resignation was not related to any disagreement with the Board regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies beyond the specific event of the director's resignation.
Key Facts for Investor Verification
- Mark Groussman resigned from the Board of Directors on June 11, 2018.
- The resignation was not caused by any disagreement with the Company.
- The filing is signed by Ascher Shmulewitz, M.D., Ph.D., Chief Executive Officer.
- No financial data is included in this specific report.